This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
A 2018 literature review of 740 records of surgeries that included recurrence rates found that primary midline closure surgeries resulted in a 67.9% recurrence rate within 20 years, and recommended that they should be discontinued due to the high recurrence rate. Incision and drainage had a recurrence rate of 25.9% within 2 years, up to 40.2% in 5 years. Phenol treatment has a recurrence rate of 14.1% at 2 years and 40.4% at 5 years. A 2024 study involving 667 people found that, compared with tissue-removing surgery, minor procedures (such as draining and pit-picking) were associated with less pain, fewer complications and a faster recovery. However, minor surgeries were less likely to resolve the condition. Surgeons can also excise the sinus and repair it with a reconstructive flap technique, such as a "cleft lift" procedure or Z-plasty, usually done under general anesthetic. This approach is especially useful for complicated or recurring pilonidal disease, leaves little scar tissue, and flattens the region between the buttocks, reducing the risk of recurrence. This approach typically results in a more rapid recovery than traditional surgery; however, there are fewer surgeons trained in the cleft lift procedure, and it consequently may not be as accessible to patients, depending on their location. Meta-analysis shows recurrence rates were lower in open healing than with primary closure (RR 0.60, 95% CI 0.42 to 0.87), at the expense of healing time.
== Description == The croaking gourami reaches an average size of about 5 cm (2.0 in), though some individuals can grow as long as 6 or 7 cm (2.4 or 2.8 in). Coloration is highly variable, ranging from pale brown and green to dark purple with black or red spots on the fins. 2 to 4 brown or black stripes or rows of spots are present on the flanks. Median fins have a thin iridescent blue coloration on their edges, and the iris is bright blue or purple. Females tend to be paler than males, with a slightly rounded dorsal fin (the dorsal fin of males is instead pointed) and a shorter anal fin.
23 August – It is reported that doctors at Oxford's Churchill Hospital have carried out the UK's first womb transplant, with a 34-year-old woman receiving her sister's womb in a 17-hour operation that took place in February 2023. 24 August Data released by the Home Office shows that 175,000 people were waiting to have their claims for asylum assessed at the end of June 2023, an increase of 44% on the same time in 2022. GCSE results are published in England, Wales and Northern Ireland, with 68.2% of all entries marked at grades 4/C and above. It is the second fall in overall results, taking them almost back to pre-pandemic levels. 25 August Ofgem confirms the energy price cap will fall again in October, with an annual gas and electricity bill at around £1,923. The National Crime Agency launches a criminal investigation after linking 88 UK deaths with an online seller from Canada accused of selling them a poisonous substance so they could commit suicide. 26 August – Conservative MP Nadine Dorries resigns her Parliamentary seat two months after originally saying she would do so, accusing Prime Minister Rishi Sunak of abandoning "the fundamental principles of Conservatism" and that "history will not judge [him] kindly". 28 August – Hundreds of flights to and from the UK are delayed following technical problems with the UK's air traffic control system.
Not only does the translation from mRNA cause differences, but many proteins also are subjected to a wide variety of chemical modifications after translation. The most common and widely studied post-translational modifications include phosphorylation and glycosylation. Many of these post-translational modifications are critical to the protein's function.
=== Research === Sherrill develops methods, algorithms, and software for quantum chemistry. He has introduced efficient density-fitting techniques into several quantum chemistry methods, speeding up computations. His research group obtains highly-accurate results for important prototype chemical systems, and uses these results to develop computational protocols that are faster yet still accurate. Sherrill focuses on intermolecular interactions, and has published definitive studies of the strength, geometric dependence, and substituent effects in prototype interactions including π-π, CH/π, S/π, and cation-π interactions. He has developed extensions of symmetry-adapted perturbation theory (SAPT) to analyze these interactions in terms of their fundamental physical forces (electrostatics, exchange/steric repulsion, induction/polarization, and London dispersion forces). A fragment-based partitioning of SAPT allows analyses of which non-bonded contacts are most important for binding, and has been used to understand substituent effects in protein-drug binding. Sherrill has published over 200 peer-reviewed articles on these topics, and presented over 130 invited lectures, including the 2011 Robert S. Mulliken Lecture at the University of Georgia, the keynote talk for the 2015 Workshop on Control of London Dispersion Interactions in Molecular Chemistry in Göttingen, and keynote talks at the 2015 and 2016 meetings of the Southeast Theoretical Chemistry Association.
Sources: en.wikipedia.org
== External links == Richard L.M. Synge on Nobelprize.org Synge's Nobel Lecture Applications of Partition Chromatography Sidney Elsden (21 June 2016), Richard Laurence Millington Synge (PDF), archived from the original (PDF) on 29 October 2007, retrieved 17 October 2007
Upon oral ingestion, EMP is rapidly and completely dephosphorylated by phosphatases into estramustine during the first pass in the gastrointestinal tract. Estramustine is also partially but considerably oxidized into estromustine by 17β-hydroxysteroid dehydrogenases during the first pass. As such, EMP reaches the circulation as estramustine and estromustine, and the major metabolite of EMP is estromustine. A limited quantity of approximately 10 to 15% of estramustine and estromustine is further slowly metabolized via hydrolysis of the normustine ester into estradiol and estrone, respectively. This reaction is believed to be catalyzed by carbamidases, although the genes encoding the responsible enzymes have not been characterized. The circulating levels of normustine formed from EMP are insignificant. Release of nitrogen mustard gas from normustine via cleavage of the carboxylic acid group has not been demonstrated and does not seem to occur. The oral bioavailability of EMP is low, which is due to profound first-pass metabolism; specifically, dephosphorylation of EMP. The oral bioavailability of EMP specifically as estramustine and estromustine is 44 to 75%, suggesting that absorption may be incomplete. In any case, there is a linear relationship between the oral dose of EMP and circulating levels of estramustine and estromustine. Consumption of calcium, aluminium, or magnesium with oral EMP can markedly impair its bioavailability due to diminished absorption from the intestines, and this may interfere with its therapeutic effectiveness at low doses.
In pharmaceutical industry, stability testing is a process that is used to determine the quality of a drug substance or drug product over a period of specified time under specific environmental conditions. With stability testing, pharmaceutical industry inspects the quality of drug substances and drug products as per the guidelines outlined by US Food and Drug Administration and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use to make sure that they retained the quality over the period of time. Stability testing depends upon the environmental factors like, light source, humidity and ambient temperature as well as the physical and chemical properties of the active drug product.
Decalcification of small bone chunks in a 1-5% hydrochloric acid solution. If further decayed organic matter remains, a soak in 0.1 molar sodium hydroxide may be required. The isolated collagen is then freeze dried. Demineralisation of small bone chunks in sodium salt to separate collagen, which is then freeze-dried Demineralisation of powdered bone in 8% hydrochloric acid, slow hydrolysis in pH 3. If required, a further soak in 0.1 molar sodium hydroxide. The latter is most effective in the instance of very poorly preserved bone, although it also faces an increased risk of contamination by other organic matter. Consequently, the supposedly isolated sample should be analysed and only tested if the readings fall within an acceptable range; most mass spectrometers now include a gas analyser as well as a combustion chamber to streamline this process.
=== Pharmacokinetics === Myristicin has been reported to have unfavorable absorption in pure state. The metabolism of myristicin and safrole has been studied. It has been theorized that allylbenzenes like myristicin, elemicin, and safrole might be metabolized via amination into the amphetamine analogues such as MMDA, TMA, and MDA, respectively, but there remains no good supporting evidence for this theory. The non-amine forms can be converted into the amine forms like TMA, MDA, and so on in the presence of ammonia in laboratory settings. In addition, MMDA has been unequivocally detected upon incubation of rat liver cells with myristicin in vitro. Similarly, administration of allylbenzene orally to rats has been found to result in detectable amphetamine in urine. However, no amphetamine metabolites were detected when myristicin was administered to mice, rats, or guinea pigs. Likewise, no amphetamine metabolites were found in a later more modern study in rats and in a human. Other research has found that allylbenzenes including myristicin, elemicin, safrole, and eugenol can in fact be metabolized into nitrogen-containing metabolites, specifically tertiary aminopropiophenones, but these metabolites are not phenethylamines nor amphetamines and their activity is unknown.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.